The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 26, 2025

Filed:

Mar. 06, 2020
Applicant:

Korea Research Institute of Bioscience, Daejeon, KR;

Inventors:

In Pyo Choi, Daejeon, KR;

Suk Ran Yoon, Daejeon, KR;

Sooyun Lee, Daejeon, KR;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 40/15 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); C12N 5/0783 (2010.01);
U.S. Cl.
CPC ...
C12N 5/0646 (2013.01); A61K 40/15 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2018.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/50 (2023.05); A61K 2239/53 (2023.05); A61K 2239/54 (2023.05); A61K 2239/55 (2023.05); C12N 2501/2315 (2013.01); C12N 2501/2321 (2013.01); C12N 2506/00 (2013.01); C12N 2509/10 (2013.01);
Abstract

Disclosed is a method for producing a large amount of natural killer cells and the use of the natural killer cells as an anticancer agent. The method produces fresh NK cells with high purity within a short time, and can also produce cold-preserved NK cells and thawed cryopreserved NK cells having efficacy comparable to the fresh NK cells. NK cells having efficacy comparable to the fresh NK cells can also be produced from cryopreserved CD3-negative cells. The fresh NK cells, cold-preserved NK cells and cryopreserved NK cells exhibit therapeutic effects against various cancers, including colorectal cancer, lung cancer, liver cancer, pancreatic cancer and leukemia, indicating these NK cells are effective as cellular therapeutic agents. Also disclosed are doses and methods of administration that show excellent effects when the fresh NK cells, cold-preserved NK cells and cryopreserved NK cells are used as pharmaceutical compositions for cellular therapy.


Find Patent Forward Citations

Loading…